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1. Introduction 
Endometrial cancer represents over 96% of uterine cancer and is the most common 
gynecologic cancer in the developed countries with an estimated prevalence of 142,200 
women diagnosed in 2011 worldwide1. 
This cancer affects mainly postmenopausal women, 95% of cases occurring in patients over 
40 years of age; nonetheless up to 14% of patients are premenopausal, and 5% of cases 
occurs under the age of 40 years. 
The 26th Annual Report of the International Federation of Gynecology and Obstetrics 
(FIGO) states that 83% of endometrial cancer patients are diagnosed and treated at early 
stage (FIGO I and II) with 5 year actuarial survival rates ranging from 85% to 91%2. 
Different treatments plans can be proposed for cancer of uterine corpus, but the standard 
treatment for this disease has been and remains hysterectomy. 
The FIGO (Fédération Internationale de Gynécologie Obstétrique) staging system for this 
pathology has been recently reviewed and approved at the TNM UICC Core Group meeting 
in Geneva at the beginning of May 20083 and subsequently adopted by the American Joint 
Committee on Cancer (AJCC). 
The proposed changes to the staging for endometrial cancer are linked to the data provided 
by the FIGO Annual Report and confirmed by other publications (Table 1). 
The surgical treatment for most patients affected by endometrial cancer includes the 
thorough a surgical exploration of the abdominal cavity with collection of free peritoneal 
fluid/ peritoneal washing for cytologic evaluation, total extrafascial hysterectomy with 
bilateral salpingoophorectomy. The traditional abdominal access is laparotomic with 
vertical midline incision. The removal of pelvic/paraortic lymph nodes is also required to 
perform an adequate staging according to FIGO guidelines. 
Usually this cancer belongs to perimenopausal age, a small percentage of cases affecting 
younger women.  
Most premenopausal patients have a favorable disease-free survival rate (93%) compared to 
older patients (86%), with a higher rate of low-grade and low-stage disease. 
The overall good prognosis in young women affected by early stage endometrial cancer 
makes fertility-sparing management an attractive option to this group of patients. 
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Stage I* Tumor confined to the corpus uteri 
IA  No or less than half myometrial invasion 
IB  Invasion to or more than half of the myometrium 
Stage II* Tumor invades cervical stroma, but does not extend beyond the uterus** 
Stage III*  Local and/or regional spread of the tumor 
IIIA  Tumor invades the serosa and/or adnexae*** 
IIIB  Vaginal and/or parametrial involvement 
IIIC  Metastases to the pelvic and/or para-aortic lymph nodes 
IIIC1  Positive pelvic nodes 
IIIC2  Positive para-aortic lymph nodes with or without positive pelvic lymph nodes 
Stage IV*  Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
IVA  Tumor invasion of bladder and/or bowel mucosa 
IVB  
Distant metastases, including intraabdominal metastases and/or inguinal 
lymph nodes 
* Either G1, G2, or G3 
** Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II 
*** Positive cytology has to be reported separately without changing the stage. 
Table 1. Endometrial Cancer: New FIGO Staging. 
The progressive increasing incidence of endometrial cancer in the last few decades 
combined with the increase of absolute number of under forty’s with childbearing desire 
have forced clinicians to consider fertility-sparing options in treatment of this pathology. 
These strategies include endocrine treatment and surgical ovarian preservation.  
Fertility-sparing endocrine treatment is founded on the use progestational agents. The 
clinical staging system proposed by the FIGO in 1971 is still applicable for patients who 
attempt for a medical fertility sparing option (table 2). 
 
Stage characteristics 
I Carcinoma is confined to the corpus 
IA Length of the uterine cavity is 8 cm or less 
IB Length of the uterine cavity is more than 8 cm 
Histologic subtypes of adenocarcinoma 
G1 Highly differentiated adenomatous carcinoma 
G2 Differentiated adenomatous carcinoma with partly solid areas 
G3 Predominantly solid or entirely undifferentiated carcinoma 
II Carcinoma involves the corpus and cervix 
III Carcinoma extends outside the uterus but not outside the true pelvis 
IV Carcinoma extends outside the true pelvis or involves the bladder or rectum 
Table 2. Corpus Cancer Clinical Staging, FIGO 1971. 
The use of progestational agents is still a subject of investigation in young patients with 
early stage disease 4,5,6 and it has been shown to have reasonable success particularly in 
women with low-grade disease 7. A recent multicenter phase II study of treatment with 
medroxyprogesterone acetate for endometrial carcinoma and for atypical hyperplasia in 
young women by Ushijima and colleagues found a complete response in 55% and 82% of 
cases respectively, with a 47% recurrence rate observed during the 2-year follow up period. 
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Progestational uterine-preserving treatment is a reasonable option in women affected by 
early stage, low-grade endometrial cancer, but these patients should be widely counseled 
about the high recurrence risk observed in cases responding to progestins (about 50% of 
cases), and thus recommended to close follow-up because of the substantial rate of 
recurrence.4 
MRI, with its high soft tissue contrast resolution and multiplanar capability, has been 
evaluated in several series. Most of them reported data on the prediction of deep 
myometrial invasion. In these series the sensitivity of the radiological procedure ranges 
between 71% to 83%, the specificity between 74% to 96% with Negative and Positive 
Predictice Values between 86%-97% and 80%-91% respectively.8 9 10  
If the requirement for conservative treatment is no myometrial invasion, then MRI is a poor 
screening test with an NPV of only 46%11. 
Ovarian preservation in young patients, preferably in early stage, low grade cases, may be 
considered taking into account the potential risk of missing occult ovarian metastases or 
coexisting synchronous ovarian primary tumors 12,5 and the potential risk of endocrine 
stimulation of residual microscopic endometrial cancer foci 13,14,15,16 
Twenty-three coexisting synchronous epithelial ovarian tumors and 3 metastatic disease 
were reported in a cohort of 102 women younger than 45 years with endometrial cancer, 
thus ovarian cancer accounting for 25% of the study cohort. In this report, 4 patients (15%) 
had normal preoperative imaging of the adnexa, and 4 (15%) had benign appearing ovaries 
at the time of intraoperative assessment. Recent results of a Surveillance, Epidemiology, and 
End Results Database (SEER) analysis on ovarian preservation applied to 402 out of 3269 
evaluable premenopausal women with stage I endometrial cancer (12%) showed that 
ovarian preservation may be safe and had no effect on either cancer-specific survival or 
overall survival. However, it must be considered that young patients could harbor a genetic 
predisposition to multiple site primary cancer 17.  
The Lynch syndrome is an autosomal-dominant cancer susceptibility syndrome associated 
with early-onset colon, rectal, ovary, small bowel, ureter/renal pelvis, and endometrial 
cancer. This syndrome occurs in nearly 10% of endometrial cancer patients less than 50 years 
of age, compared to the 2% to 5% of all endometrial cancer cases, and the risk of ovarian 
cancer in patients affected by HNPCC is 10% to 12%. 
The omission of a bilateral salpingo-oophorectomy should be carefully counseled in these 
young high-risk patients, and all the known devices should be used to best define their 
effective risk of ovarian cancer, such as genetic evaluation of mismatch repair defects or 
BRCA1 and BRCA2 germ line gene mutations. 
However in the preoperative counseling the clinician has to make the patient clearly 
understanding that a negative genetic evaluation does not eliminate the risk of synchronous 
or metachronous ovarian cancers.  
Usually, overall surgical cure rates for endometrial cancer are high but, unfortunately, up to 
25% of affected patients have a poor prognosis when the disease is widely spread at diagnosis 
or characterized by poor clinical-pathological risk factors such as high grade of histological 
differentiation, deep myometrial invasion or unfavorable histology (clear cells / serous 
papillary pattern). Treatment planning must be tailored depending on tumor grade, depth of 
myometrial invasion, and extension to cervical stroma: these factors are directly related to the 
risk of regional lymph node and distant metastasis, influencing overall prognosis. 
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Laparotomic surgery has been considered the standard surgical approach in patients 
affected by endometrial cancer. This surgery must include an initial exploration of the 
abdominal and pelvic cavities, peritoneal free fluid or washing collection for cytology, 
biopsy of any suspicious extra uterine lesion, total extrafascial hysterectomy with bilateral 
salpingo-oophorectomy. In order to complete the surgical staging, the dissection of pelvic 
and para-aortic lymph nodes are recommended by FIGO. 
Vaginal hysterectomy has often been defined as the simplest and least morbid approach and 
different studies found similar treatment outcomes in stage I endometrial cancer patients 
treated with vaginal or laparotomic hysterectomy 18,19,20. Still, limitations to vaginal approach 
are the lack of exploration and of cytological evaluation of the abdominal cavity, difficulty in 
performing salpingo-oophorectomy and the inability to perform a thorough evaluation of 
lymph nodes 19. This surgical approach should be considered a valid alternative for high-risk 
patients with co-morbidities that can contraindicate abdominal procedures.21,22 
In the latest years, hysterectomy and bilateral salpingo-oophorectomy performed by a 
laparoscopic-assisted-vaginal (LAVH) or total laparoscopic (TLH) approach have 
increasingly been integrated in the standard practice of endometrial cancer patients. These 
techniques are able to overcome some of the limitations of the vaginal approach. 
Initial case reports and small single-institution retrospective series described laparoscopic 
technique and demonstrated its feasibility during the early '90s 23,24,25; subsequently larger 
series, randomized small size trial, and finally a multi-institutional randomized controlled 
trial, evaluated the feasibility and survival outcomes of laparoscopy in endometrial cancer 
patients 26,27,28,29. A small prospective trial 26 randomized 70 patients with FIGO stage I-III 
endometrial carcinoma to radical vaginal or laparoscopy-assisted simple hysterectomy or 
simple or radical abdominal hysterectomy with or without lymph node resection. The 
laparoscopic group showed significantly lower blood loss and transfusion rates, while the 
number of pelvic and para-aortic lymph nodes, duration of surgery, and incidence of 
postoperative complications were similar for both groups. A significantly shorter hospital 
stay was found in the laparoscopic group, in accordance with other Authors 35,36. No 
significant differences were observed between the laparoscopic and laparotomy groups in 
terms of disease recurrence rate and long-term survival (97.3% vs. 93.3% and 83.9% vs. 
90.9%, respectively).  
The conclusion of this study was that laparoscopic staging combined with laparoscopically 
assisted vaginal hysterectomy can be recommended for the treatment of women with 
endometrial cancer, offering a less invasive approach that is associated with less 
intraoperative and postoperative morbidity. 
Results of a large randomized trial (LAP II trial) from the Gynecologic Oncology Group 
(GOG) comparing laparoscopic hysterectomy with comprehensive surgical staging to the 
traditional laparotomy technique were recently published 29,30.  
The study enrolled 2616 patients with clinical stage I to IIA uterine cancer and randomized 
920 patients to the open arm, and 1,696 to laparoscopy. The conversion rate from 
laparoscopy to open procedure was 26%; it increased with increasing patient obesity. 
Median number of removed pelvic nodes was similar between each technique, while a 
statistically significant higher para-aortic node dissection rate was observed in the 
laparotomy group (97% versus 94%). Most importantly, the frequencies of patients found to 
have positive lymph nodes were the same in both groups (9%). The rate of postoperative 
complications, median blood loss, and median length of hospital stay were significantly 
lower in the laparoscopy group, despite the relatively high conversion rate.  
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The authors concluded that laparoscopic surgical staging is an acceptable and possibly a 
better option, particularly when the surgery can be successfully completed laparoscopically, 
even if the results specific to long-term oncologic outcomes are not known. 
Age and obesity have been suggested as relative contraindications to laparoscopic surgery. 
Similar conclusions where reached by Scribner et al. 31 
The authors concluded that, with the growth of an aging patient population, the 
laparoscopic management of endometrial cancer is a viable option. 
Obese patients have also been suggested to be poor laparoscopic candidates due to 
difficulties in establishing pneumoperitoneum, poorer visualization, inability to tolerate 
steep Trendelenburg positioning needed to facilitate the surgery, and difficulties with 
ventilation. It is important to mention that complete surgical staging is more difficult in 
obese patients regardless of the surgical approach.  
In a study of Eltabbakh et al. comparing LAVH and abdominal approach in women with 
BMI between 28 and 60 32 laparoscopic conversion was required only in 8% of patients: 
laparoscopic surgery was associated with a longer operative time (195 
minutes vs. 138 minutes), more pelvic nodes (mean 11 vs. 5), less pain medicine 
requirement, and shorter hospital stay (2.5 vs. 5.6 days) were recorded.  
Total laparoscopic hysterectomy has also been shown to be feasible in heavier patients 33. In 
the prospective GOG series, there was ≥80% success rate with patients with a BMI of 27 or 
less, but even at a BMI of 35, 65% could have successful laparoscopic surgery. 34 
In conclusion, the surgical approach and the technique used to remove the uterus with the 
ovaries does not represent a source of controversy since the comprehensive surgical 
pathological evaluation should be accomplished with different approaches. 25 
Minimal access surgery is being applied increasingly in gynecological oncology and is now 
a commonplace in the surgical treatment of endometrial cancer. 
The widespread adoption of laparoscopy has been slow due to the prolonged learning curve 
needed to become proficient in such a technique. The development of robotic surgery has 
facilitated the use of laparoscopy due to the faster and easier learning curve.  
In robotic surgery, the main surgeon sits at the surgeon console located away from the 
patient, places his index fingers and thumbs in the master rings and along with foot pedals 
is able to control all the robotic instruments held by the patient-side cart through a 
computer-based technology. Endometrial cancer is particularly suited for robotic surgery for 
several reasons. The majority of women with endometrial cancers are obese and at greater 
risk for postoperative wound complications, and would benefit from a minimally invasive 
procedure with smaller incisions, resulting in less risk for wound problems. However, at the 
same time obesity increases the degree of difficulty of management via laparoscopy: the 
level of difficulty of operating in an obese patient via robotic surgery is minimal. In a 
retrospective comparison of obese women and morbidly obese women undergoing 
traditional laparoscopic approach vs. robotic-assisted approach, better surgical outcomes 
were observed in the group undergoing robotic-assisted laparoscopy. 35  
Actually there are no published data of survival in endometrial cancer patients treated with 
robotic system that has been introduced in clinical practice short time ago. However, early 
case series thus far reported suggests that robotic surgery for endometrial cancer is feasible 
and safe. The use of robotic-assisted laparoscopy for the management of endometrial cancer 
is expected to be rapid, paralleling the growth that has been observed with radical 
prostatectomy. 
Another important issue in the management of endometrial cancer is the tailoring of 
“radicality” according to the “clinical stage” of the disease. 
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Radical hysterectomy is the standard of care of early stage cervical cancer (IA2–IB1), but its 
role in endometrial cancer remains unclear 36. A radical surgical approach to endometrial 
cancer requires the uterus to be removed with parametria, paracolpos, and an adequate 
vaginal cuff, and ensures wider tumor-free resection margins than those obtained with total 
abdominal hysterectomy. The main goals of the radical surgical approach for stage I 
endometrial cancer are a better local control of the disease and a reduction in the use of 
adjuvant radiation with its possible related complications. 
A multicenter randomized Italian trial 37 aimed to determine whether a modified radical 
(Piver– Rutledge class II) hysterectomy can improve survival and loco regional control 
compared to the standard extrafascial (Piver–Rutledge class I) hysterectomy. The Authors 
randomized 520 early stage endometrial cancer patients and evaluated the difference 
between Class I vs. Class II group in terms of loco regional control, disease-free and overall 
survival, and treatment-related morbidity.  
Intraoperative and postoperative complications rates were similar in the two arms, but there 
were slight imbalances with respect to urinary complications. Although class II 
hysterectomy turned out to be feasible in most patients enrolled onto our study (only 19 of 
the 279￼assigned to class II underwent class I hysterectomy), it was far longer (20 min) and 
was associated with greater blood loss (50 ml) than class I.  
The univariate and multivariate estimates of the HRs of recurrence confirm that class II 
hysterectomy offers no benefit. 
The identification of spread to draining lymph node basins is considered of outmost 
importance since it can change the prognosis and modify the use of postoperative therapies. 
However no consensus exists regarding the role and the extension of lymphadenectomy in the 
primary surgical setting and more controversial is the therapeutical role of this procedure.  
In women submitted to systematic lymphadenectomy without clinical suspect of nodal 
metastasis, pelvic lymph node involvement may be assessed in 8 to 28% of patients. 38, 39.  
The risk of pelvic and/or paraortic nodal metastases 2 depends on hystotype, myometrial 
invasion and hystological grade of differentiation, ranging from 0% up to 20% in M0G1 and 
M3G3 patients (see Table 3). 
 
Myometrial invasion P-A-(%) P+A-(%) P-A+(%) P+A+(%) 
Unknown 97.42 1.81 0.17 0.60 
M0 94.20 3.40 0.60 1.80 
M≤50% 93.88 4.56 0.62 0.94 
M>50% 73.90 18.41 1.56 6.14 
P-, P+: negative, positive pelvic nodes; 
A-, A+: negative, positive aortic nodes; 
M0: no myometrial invasion 
M≤50%: myometrial invasion ≤50% 
M>50%: myometrial invasion >50 %. 
Table 3. Carcinoma of the corpus uteri. Patients treated in 1999-2001. Lymhnodal status (a). 
Even if there is no evidence that risk/benefit balance is in favor of lymphadenectomy however 
this procedure can cause potentially significant morbidity in approximately 11% of cases 40. 
The relevance of lymph node status is of outmost importance for the prognosis of this disease. 
For this reason this procedure represents a fundamental step in staging the disease 3. The main 
risks attributable to nodal dissections include increased operative time, potential for blood 
loss associated with vascular injuries eventually requiring blood transfusion, genitofemoral 
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nerve injury with resulting numbness and paresthesias over medial thighs, lymphocysts 
formation, and lymphedema. 
Many believe that nodal dissection should be reserved for those with sufficient risk of nodal 
disease. Most important factors related to incidence of nodal metastases are tumor grade 
and depth of myometrial invasion as we can see analyzing data of GOG 33 study 38. Patients 
with grade 1 lesion with inner part of myometrium involved showed a 3% risk of nodal 
metastasis defined by the Authors “negligible”. Patients with grade 3 lesions with deep 
myometrial invasion showed a 34% risk of nodal localizations. 
Clear cell tumors and serous papillary tumors are more often affected by nodal metastasis 
(30-50% of risk independently by prognostic factors on surgical specimen) 41. 
Usually the risks related to nodal resection are acceptable, if this procedure is managed by 
skilled and well trained physicians, and this procedure deeply influences the use of 
postoperative treatment: less indications for radiation therapy or use of vaginal cuff 
brachytherapy instead of whole pelvic external irradiation 42 43. Without nodal information, 
physicians must rely on uterine factors to estimate the probability for nodal disease and 
pelvic failure to determine the need for postoperative radiation. This estimation can result in 
a substantial increase in the use of radiation. 
The advantages of systematic lymphadenectomy are evidenced in some retrospective 
studies. Other observational studies, however, have not shown any such benefit. Until 2011 
no class I evidence paper had been published. 
MRC ASTEC trial 44 enrolled 1408 women with proven endometrial carcinoma from 85 
centers in four countries. 
This randomized trial did not showed any evidence of benefit with systematic 
lymphadenectomy for endometrial cancer in terms of overall, disease-specific, and 
recurrence-free survival. Overall morbidity was low, but there was a substantial increase in 
the incidence of lymphedema in the lymphadenectomy group compared with standard 
surgery. The Authors concluded that the balance of risks and benefits for systematic iliac 
and obturator lymphadenectomy does not favor this intervention, with no clear evidence of 
benefit in terms of overall or recurrence-free survival and increased risk of lymphedema.  
These results suggest that lymphadenectomy in patients affected by endometrial cancer, 
whose neoplasm is preoperatively diagnosed as confined to the corpus, has no therapeutic 
effect and is therefore not justified as a therapeutic procedure. Nevertheless this surgical 
procedure is required for surgical staging in order to identify those patients who will have 
benefit from adjuvant treatment. 
It must be noted that this trial received a number of criticisms concerning the inclusion of a 
large number of women at low risk of nodal metastases and variable extent of nodal 
dissection between recruiting centers. 
An Italian randomized prospective study 45 recruited 514 patients with preoperative FIGO 
stage I endometrial carcinoma (Stage IB with grade 1 lesions were excluded from 
randomization), randomly assigned to undergo pelvic systematic lymphadenectomy or no 
lymphadenectomy whose anatomical and numerical extent was clearly defined in the study 
design. No lack of consistency between the centers and uniformly high nodal counts were 
detected.  
According to the Authors, pelvic systematic lymphadenectomy did not change the natural 
history of the disease since the pattern of disease recurrence, was similar between the two 
groups. However, pelvic lymphadenectomy did allow for a more accurate prognosis on the 
basis of the pathological lymph node assessment and, in this trial, provided for 
approximately 10% of the upstaging to surgical stage IIIC (P < .001). 
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The role of para-aortic lymphadenectomy is another field of debate: the anatomic extent and 
level of dissection remain ill defined for patients undergoing para-aortic node sampling or 
systematic dissection. 46,47,48,49 
Reports that address the routes of lymphatic dissemination in endometrial cancer have 
suggested that the principal connections are between the uterine corpus and the external 
iliac and obturator basins 50,51,52. A direct route may exist from the corpus to the paraaortic 
node-bearing basins by the lymphatic channels adjacent to the gonadal vessels within the 
infundibulopelvic ligament 51,52. Other reports have also suggested a potential direct 
lymphatic communication between the external iliac and obturator basins and the paraaortic 
node-bearing tissue 48,53. Therefore, an a priori assertion exists that the paraaortic node-
bearing tissue in the region of the origin and insertion of the gonadal arteries and veins, 
respectively, would be favored sites for nodal involvement. 
In absence of metastatic pelvic nodes, isolated positive para-aortic nodes are identified in a 
small number of patients. The historical data from GOG 33 showed that isolated para-aortic 
nodal metastases occurred in 2% of patients. These data also suggest that when positive, 
outcomes are improved in patients who have complete surgical resection of para-aortic nodes. 
This effect may be simply be a consequence of better staging rather than a true therapeutic 
effect. Another explanation may be that extensive lymphadenectomy reflects overall better 
care. The use of Radiation therapy responding to positivity of para-aortic nodes may be 
another explanation of better survival in patients submitted to this procedure 54.  
The risks of paraortic nodal involvement are essentially the same that predicts the pelvic nodal 
spread (depth of myometrial invasion, nuclear grading, and the presence of lymph-vascular 
space involvement) 46,55. Mariani et al. showed that patients at high risk for para-aortic nodal 
disease (based on invasion >50%, palpable positive pelvic nodes, positive adnexa) who did not 
have para-aortic dissection or who had biopsy only and who were managed as though para-
aortic nodes were positive had 5-year survival of 71% compared to 85% for those patients with 
positive para-aortic nodes who did undergo complete resection 56.  
At the present time, the superior extent of para-aortic dissection should be at least to the 
level of the inferior mesenteric artery (IMA). The Mayo Clinic group retrospectively in their 
series observed that the routinely performed lymphadenectomies only up to the IMA 
potentially miss 38% to 46% of patients with positive para-aortic nodes because of the high 
rate of isolated involvement above the IMA. Furthermore, 63% of patients in Mayo’s series 
with positive lymph nodes below the IMA also had positive nodes above the IMA that 
would have escaped detection if the dissection had been limited to the lower node basins. 
Thus, the node-bearing tissue between the IMA and the renal vessels appears in their 
experience of outmost importance for the assessment of the extent of disease and thus for 
determination of overall treatment dispositions. 56 This extended para-aortic dissection is 
feasible laparoscopically as well laparotomically 57. Prospective data describing the 
frequency of high para-aortic/renal nodes are awaited. 
More recently a large prospective trial compared the outcomes after complete pelvic 
lymphadenectomy or combined pelvic and para-aortic lymphadenectomy. The trial was 
non-randomized and was conducted at two sites, one in which pelvic lymphadenectomy 
was standard and a second where combined pelvic and para-aortic dissection was standard. 
More than 600 women were included. The authors report significantly increased overall 
survival in women undergoing para-aortic dissection and argue that women at intermediate 
or high risk of disease recurrence should have both pelvic and para-aortic 
lymphadenectomy 58. No benefit was seen in low risk patients. Although the groups were 
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comparable in most respects with a similar proportion of non-endometrioid carcinomas, 
77% of women in the pelvic/para-aortic group received systemic chemotherapy compared 
with only 45% of women in the pelvic node group. These results do not argue convincingly 
for para-aortic lymphadenectomy in women at higher risk of disease recurrence or distant 
metastasis but do suggest that this is an area that should be addressed by a properly 
constructed clinical trial. 
A recent Cochrane Review 59 assessed that published data do not support the routine use of 
pelvic lymphadenectomy in the treatment of endometrial cancer thought to be confined to the 
uterus at presentation. There was no statistically significant difference in survival between the 
groups. Meta-analysis indicated no significant difference in overall and recurrence-free 
survival between women who received lymphadenectomy and those who received no 
lymphadenectomy (pooled HR = 1.07, 95% CI: 0.81 to 1.43 and HR = 1.23, 95% CI: 0.96 to 1.58 
for overall and recurrence-free survival respectively) and, in terms of harmful effects of 
treatment, women who did not receive lymphadenectomy showed a clear benefit. No good 
quality data were found which assessed the role of para-aortic lymphadenectomy, or removal 
of grossly enlarged lymph nodes. Further research is needed to allow more individualized 
treatment strategies, ensuring that women with more aggressive cancers receive appropriate 
treatment, whilst not exposing women with a better prognosis to potentially serious side 
effects. In addition, it is imperative to assess the impact of any intervention on quality of life in 
any future study, particularly for a cancer with good survival rates. 
Although lymphadenectomy continues to be controversial for some, over the last 30 years 
our knowledge of the lymph node involvement in endometrial cancer has increased and 
how that information can be used to benefit our patients. Lymphadenectomy in endometrial 
cancer is certainly diagnostic and it may be also therapeutic if systematic pelvic and para-
aortic procedures are performed. At the present time low risk patients can avoid this 
surgical assessment but there is no general agreement in the definition of the “low risk 
category”. Recent data, and a new molecular staging system could improve our knowledge 
and would probably lead to a consensus in the near future. 
2. Debulking 
Endometrial cancer is often diagnosed at a stage I disease (71%) 60. A low percentage of 
cases present at an advanced stage, defined by FIGO stage III and IV. Nonetheless, rare 
histopathologic types of endometrial cancer, such as papillary-serous (4% of cases) and clear 
cell carcinomas (2% of cases) frequently present at an advanced stage, both accounting for 
14% of advanced stage (FIGO III and IV) compared with 4% of early stage (FIGO I and II) 
endometrial cancer patients 61,62. 
The management of endometrial cancer is reviewed in several papers; still, limited evidence 
is available how to manage patients with advanced stage disease. The treatment of  this 
relatively rare group of patients is frequently individualised and it depends on the surgical 
ability to resect disease. 
In patients with macroscopic intraperitoneal disease it is debated if optimal surgical 
cytoreduction is indicated, and in these cases options include the resection of the easily 
removable disease such as uterus, adnexa, and omentum, versus performing a wider 
cytoreductive effort. Different retrospective studies evaluated the impact of surgical 
cytoreduction on the outcome of advanced endometrial cancer patients, suggesting that 
survival correlates with the volume of residual disease. 
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Goff et al 63 analysed 47 cases of stage IV endometrial cancer, observing a statistically 
significant improvement of median survival  in the cases of no bulky disease at the end of 
surgery compared to patients not completely cytoreducted (18 vs. 8 months respectively). 
Chi et al 64 also found a significatively longer median survival in the subgroup of patients 
treated with optimal cytoreduction (residual tumor < 2 cm) among 55 cases of stage IV 
endometrial cancer, compared to patients with residual tumor > 2 cm (31 months vs. 12 
months).  
Bristow et al 65 defines optimal cytoreduction as largest residual tumor < 1 cm and showed 
that median survival was 34 months after optimal cytoreduction compared to 11 months 
when suboptimal cytoreduction was performed, with a residual tumor > 1 cm, and again the 
difference were statistically significative.  
In conclusion, it can be assessed that in all cases with no firm contraindication for surgery, 
primary treatment should include surgery, with an exception for patients with distant 
metastases: for these cases there may be a limited role of surgery such as to provide control 
of vaginal bleeding. 
Still, the warranty for an optimal cytoreduction in cases with disease outside the uterus is only 
based on some retrospective studies made on relative small number of patients, different stage 
of disease are often included and different definitions of surgical  cytoreduction are employed. 
Thus, these studies are difficult to compare, and no randomized trial has been carried out to 
confirm the advantage of optimal cytoreduction on survival. 
Nonetheless, available data suggest that an optimal cytoreduction in advanced stage 
endometrial cancer is associated with improved survival of these patients. 
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